FDA Approves Bosutinib for Chronic-Phase Chronic Myeloid Leukemia

The FDA has granted efficacy-accelerated approval of bosutinib monohydrate (Bosulif®, Pfizer) for patients with newly diagnosed chronic-phase Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). "Management of chronic myeloid leukemia has changed significantly since the development of tyrosine kinase inhibitors (TKIs), with greatly improved response rates and lower risk of transformation translating into a relative survival similar to that of the general population," w...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.